La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Tianshui Zhongxing Bio-technologyLtd Salute del bilancio

Salute finanziaria criteri di controllo 3/6

Tianshui Zhongxing Bio-technologyLtd ha un patrimonio netto totale di CN¥3.3B e un debito totale di CN¥2.4B, che porta il suo rapporto debito/patrimonio netto a 70.3%. Le sue attività totali e le sue passività totali sono rispettivamente CN¥6.2B e CN¥2.8B. L'EBIT di Tianshui Zhongxing Bio-technologyLtd è CN¥17.7M rendendo il suo rapporto di copertura degli interessi 0.8. Ha liquidità e investimenti a breve termine pari a CN¥1.5B.

Informazioni chiave

70.3%

Rapporto debito/patrimonio netto

CN¥2.35b

Debito

Indice di copertura degli interessi	0.4x
Contanti	CN¥1.50b
Patrimonio netto	CN¥3.35b
Totale passività	CN¥2.83b
Totale attività	CN¥6.17b

Aggiornamenti recenti sulla salute finanziaria

Nessun aggiornamento

Recent updates

These Return Metrics Don't Make Tianshui Zhongxing Bio-technologyLtd (SZSE:002772) Look Too Strong

Oct 01

Tianshui Zhongxing Bio-technologyLtd (SZSE:002772) Has Affirmed Its Dividend Of CN¥0.30

May 12

Tianshui Zhongxing Bio-technology Co.,Ltd. (SZSE:002772) Held Back By Insufficient Growth Even After Shares Climb 37%

Mar 15

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( CN¥2.8B ) di 002772 superano le sue passività a breve termine ( CN¥1.3B ).

Passività a lungo termine: Le attività a breve termine di 002772 ( CN¥2.8B ) superano le sue passività a lungo termine ( CN¥1.5B ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 25.4% ) di 002772 è considerato soddisfacente.

Riduzione del debito: Il rapporto debito/patrimonio netto di 002772 è aumentato da 62.9% a 70.3% negli ultimi 5 anni.

Copertura del debito: Il debito di 002772 non è ben coperto dal flusso di cassa operativo ( 15.2% ).

Copertura degli interessi: I pagamenti degli interessi sul debito di 002772 non sono ben coperti dall'EBIT ( 0.8 x copertura).

Tianshui Zhongxing Bio-technologyLtd Salute del bilancio

Salute finanziaria criteri di controllo 3/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Recent updates

These Return Metrics Don't Make Tianshui Zhongxing Bio-technologyLtd (SZSE:002772) Look Too Strong

Tianshui Zhongxing Bio-technology Co.,Ltd. to Report Q3, 2024 Results on Oct 26, 2024

Second quarter 2024 earnings released: CN¥0.013 loss per share (vs CN¥0.002 loss in 2Q 2023)

Tianshui Zhongxing Bio-technology Co.,Ltd. to Report First Half, 2024 Results on Aug 16, 2024

Tianshui Zhongxing Bio-technologyLtd (SZSE:002772) Has Affirmed Its Dividend Of CN¥0.30

Dividend of CN¥0.30 announced

Tianshui Zhongxing Bio-technology Co.,Ltd. Announces Dividend Implementation of 2023 Final Profit Distribution, Payable on 16 May 2024

First quarter 2024 earnings released: EPS: CN¥0.088 (vs CN¥0.50 in 1Q 2023)

Tianshui Zhongxing Bio-technology Co.,Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Tianshui Zhongxing Bio-technology Co.,Ltd., Annual General Meeting, Apr 16, 2024

Full year 2023 earnings released: EPS: CN¥0.39 (vs CN¥0.40 in FY 2022)

Tianshui Zhongxing Bio-technology Co.,Ltd. (SZSE:002772) Held Back By Insufficient Growth Even After Shares Climb 37%

Investor sentiment improves as stock rises 19%

Investor sentiment deteriorates as stock falls 15%

Tianshui Zhongxing Bio-technology Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 26, 2024

Third quarter 2023 earnings released: CN¥0.056 loss per share (vs CN¥0.36 profit in 3Q 2022)

Tianshui Zhongxing Bio-technology Co.,Ltd. to Report Q3, 2023 Results on Oct 28, 2023

Second quarter 2023 earnings released: CN¥0.002 loss per share (vs CN¥0.088 loss in 2Q 2022)

Tianshui Zhongxing Bio-technology Co.,Ltd. to Report First Half, 2023 Results on Aug 19, 2023

Upcoming dividend of CN¥0.30 per share at 2.8% yield

Investor sentiment improves as stock rises 17%

Full year 2022 earnings released: EPS: CN¥0.40 (vs CN¥0.14 in FY 2021)

Less than half of directors are independent

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.36 (vs CN¥0.16 loss in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.088 loss per share (vs CN¥0.084 loss in 2Q 2021)

Tianshui Zhongxing Bio-Technology Co.,Ltd. Announces 2021 Final Profit Distribution Plan, Payable on 19 May 2022

Less than half of directors are independent

Tianshui Zhongxing Bio-technology Co.,Ltd. Approves Cash Dividend for 2021

Third quarter 2021 earnings released: CN¥0.16 loss per share (vs CN¥0.19 profit in 3Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Second quarter 2021 earnings released: CN¥0.084 loss per share (vs CN¥0.054 loss in 2Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Tianshui Zhongxing Bio-technology Co.,Ltd. (SZSE:002772) signed a letter of intent to acquire Guizhou Moutai Shengjiao Wine Industry Co., Ltd. from Liu Liangyue.

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.22 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.56 (vs CN¥0.19 in FY 2019)

Tianshui Zhongxing Bio-technology Co.,Ltd. to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day low: CN¥8.86

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

New 90-day high: CN¥11.30

New 90-day high: CN¥9.97

Third quarter earnings released

Tianshui Zhongxing Bio-technology Co.,Ltd. to Report Q3, 2020 Results on Oct 22, 2020

Tianshui Zhongxing Bio-technology Co.,Ltd. to Report First Half, 2020 Results on Aug 22, 2020

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane